MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
A holder of common stock has filed a Rule 144 notice to sell 359 shares of the issuer’s common stock. The filing states an aggregate market value of $29,333.89 for these shares, to be sold through Bernstein Institutional Services LLC on the NYSE, with an approximate sale date of December 19, 2025. The 359 shares were originally acquired by purchase from Goldman Sachs on December 19, 2014, with cash payment made on December 24, 2014.
The notice also lists prior sales during the past three months by related accounts, including 333 shares of common stock sold on October 1, 2025 for gross proceeds of $27,282.69 and 335 shares sold on December 1, 2025 for gross proceeds of $25,563.85. By signing, the seller represents they are not aware of any undisclosed material adverse information about the issuer.
MetLife-related accounts filed a notice to sell a small block of the issuer's common stock under SEC Rule 144. The filing covers a proposed sale of 38 shares of common stock through Bernstein Institutional Services LLC on the NYSE, with an aggregate market value of $3,104.98. The table notes that 658,891,656 shares of this class were outstanding.
The seller acquired these 38 shares in a cash purchase from Bank of America on 12/17/2019, with payment made on 12/19/2019. The notice also lists prior sales over the past three months by various MetLife-related accounts, including Separate Account II, Separate Account SPI, Separate Account 149, the MetLife 401k Plan Trust–Large Cap Equity Index, and the MetLife 401k Plan Russell 1000 Value, each selling modest amounts of common stock with disclosed dates and gross proceeds.
A holder of MetLife (MET) common stock filed a notice to sell 137 shares of common stock under Rule 144. The shares are to be sold through Bernstein Institutional Services LLC on or about 12/19/2025, with an indicated aggregate market value of 11,194.27. The filing notes that 658,891,656 shares of the issuer’s common stock were outstanding, providing context for the size of this planned sale.
The notice also lists multiple sales of the same issuer’s common stock over the prior three months by various MetLife-related accounts, each with its own share amount and gross proceeds. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
MetLife-related accounts have filed a Rule 144 notice to sell a small block of MET common stock. The filing covers a proposed sale of 10 shares of common stock through Bernstein Institutional Services LLC, with an aggregate market value of 817.1, out of 658,891,656 shares outstanding, on or about 12/19/2025 on the NYSE.
The 10 shares to be sold were acquired by purchase from Citigroup Global Markets on 10/11/2021 and paid for in cash on 10/13/2021. The notice also lists prior sales over the past three months by various MetLife accounts and plan trusts, including small transactions such as 335 shares sold for 25,563.85 and 333 shares sold for 27,282.69.
MetLife accounts filed a notice on Form 144 to sell 231 shares of common stock through Barclays on the NYSE, with an aggregate market value of $19,006.68. This is a small number of shares compared with 658,891,656 shares outstanding.
The shares were originally purchased for cash on 12/17/2019 from Bank of America, with payment made on 12/19/2019. The filing also lists several prior common stock sales over the past three months by MetLife retirement and separate accounts, including 333 shares sold by the MetLife 401k Plan Trust-Large Cap Equity Index for $27,282.69 and 335 shares sold by Separate Account SPI for $25,563.85.
MetLife, Inc. reported that one of its directors acquired additional common stock through a routine plan-related transaction. On 12/09/2025, the director obtained 687 shares of MetLife common stock at $77.82 per share, described as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 102,754 shares of MetLife common stock in direct form.
A MetLife, Inc. director reported a small increase in holdings through automatic dividend reinvestment under the company’s Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director acquired 11 shares of MetLife common stock at $77.82 per share via an imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owns 1,469 shares of MetLife common stock in direct form. The transaction was reported on a Form 4 as required for company insiders.
MetLife, Inc. director reports additional common stock from dividend reinvestment. On 12/09/2025, the director acquired 324 shares of MetLife common stock at $77.82 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. After this transaction, the director beneficially owned 44,776 shares directly and 10 shares indirectly through the MetLife Policyholder Trust, which holds stock allocated to eligible policyholders of Metropolitan Life Insurance Company.
MetLife, Inc. reported a small insider activity by one of its directors. On 12/09/2025, the director acquired 54 shares of MetLife common stock through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a price of $77.82 per share. Following this automatic dividend reinvestment, the director directly beneficially owns 7,425 shares of MetLife common stock.
MetLife, Inc. director reported a routine change in ownership of common stock linked to a compensation plan. On 12/09/2025, the director acquired 31 shares of MetLife common stock at $77.82 per share through imputed dividend reinvestment on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director directly beneficially owned 4,292 MetLife common shares. The filing notes that deferred shares are amounts that have become payable but that the director has chosen to defer receiving.